STAAR Surgical Reports 111% YoY Sales Surge in Q1 2026, Driven by China
Event summary
- STAAR Surgical's preliminary Q1 2026 net sales exceeded $90M, up from $42.6M in Q1 2025.
- China accounted for the majority of the sales increase, with continued double-digit growth in the Americas.
- Geopolitical and macroeconomic challenges caused sales declines in parts of the Middle East, EMEA, and APAC regions.
- Distributor inventory in China is now within STAAR's targeted range after working through excess stock in Q1 2025.
- The company expects meaningful improvement in adjusted EBITDA due to higher sales and improved cost structure.
The big picture
STAAR Surgical's strong Q1 2026 performance highlights its growing dominance in the phakic IOL market, particularly in China. The company's ability to navigate geopolitical risks and maintain profitability will be critical as it competes with other medical device manufacturers in the vision correction space. With over 4 million ICLs sold globally, STAAR's strategic focus on revenue growth and cost efficiency positions it for further expansion, though external market conditions remain unpredictable.
What we're watching
- China Dependence
- How STAAR's heavy reliance on the Chinese market will affect its resilience to regional volatility.
- Geopolitical Risks
- Whether macroeconomic challenges in the Middle East and EMEA will spread to other regions.
- Profitability Trends
- The pace at which STAAR can sustain improved adjusted EBITDA amid global business conditions.
Related topics